Chimeric Therapeutics Ltd
ASX:CHM

Watchlist Manager
Chimeric Therapeutics Ltd Logo
Chimeric Therapeutics Ltd
ASX:CHM
Watchlist
Price: 0.003 AUD Market Closed
Market Cap: 9.8m AUD

Intrinsic Value

The intrinsic value of one CHM stock under the Base Case scenario is 0.006 AUD. Compared to the current market price of 0.003 AUD, Chimeric Therapeutics Ltd is Undervalued by 47%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CHM Intrinsic Value
0.006 AUD
Undervaluation 47%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Chimeric Therapeutics Ltd

What is Valuation History?
Compare CHM to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CHM?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Chimeric Therapeutics Ltd
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Chimeric Therapeutics Ltd

Balance Sheet Decomposition
Chimeric Therapeutics Ltd

Current Assets 7.2m
Cash & Short-Term Investments 5.1m
Receivables 2m
Other Current Assets 121.6k
Non-Current Assets 11.5m
Intangibles 11.5m
Efficiency

Free Cash Flow Analysis
Chimeric Therapeutics Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Chimeric Therapeutics Ltd

Revenue
0 AUD
Operating Expenses
-17.6m AUD
Operating Income
-17.6m AUD
Other Expenses
-207.1k AUD
Net Income
-17.8m AUD
Fundamental Scores

CHM Profitability Score
Profitability Due Diligence

Chimeric Therapeutics Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
24/100
Profitability
Score

Chimeric Therapeutics Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

CHM Solvency Score
Solvency Due Diligence

Chimeric Therapeutics Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
46/100
Solvency
Score

Chimeric Therapeutics Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CHM Price Targets Summary
Chimeric Therapeutics Ltd

There are no price targets for CHM.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Chimeric Therapeutics Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for CHM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CHM stock?

The intrinsic value of one CHM stock under the Base Case scenario is 0.006 AUD.

Is CHM stock undervalued or overvalued?

Compared to the current market price of 0.003 AUD, Chimeric Therapeutics Ltd is Undervalued by 47%.

Back to Top